Table 1.
Description of the Amsterdam cohort and the MGH cohort
| Amsterdam cohort: severe COVID-19 patients >7 days ICU | MGH cohort: all COVID-19 cases | MGH cohort: mild-moderate COVID-19 cases | MGH cohort: severe COVID-19 cases | |
|---|---|---|---|---|
| Demographics | ||||
| Participant, N | 31 | 297 | 217 | 79 |
| Age years or N/category (20-34/35-49/50-64/65-79/80 + years) | 63 ± 11 years | 32/66/87/61/53 | 30/52/65/33/37 | 2/14/22/28/14 |
| Male, N (%) | 23 (74%) | — | — | — |
| Duration of ICU admission | 28 ± 18 | — | — | — |
| Duration of mechanical ventilation | 27 ± 17 | — | — | — |
| Days between detubation and discharge to ward | 4 ± 5a | — | — | — |
| Clinical outcomes | ||||
| Mortality day 90, N (%) | 7 (23%) | 23 (8%) | NA | 23 (29%) |
| Transferred before detubation, N (%) | 4 (10%) | — | — | — |
| Presence of delirium 2 days after detubation, (Y/N) | 18/4 | — | — | — |
| Presence of delirium 5 days after detubation (Y/N) | 14/7 | — | — | — |
| Total duration delirium in days | 6 ± 6.5 | — | — | — |
| Baseline markers (pg/mL) and SOFA score | Baseline markers in NPX values | |||
| Neurofilament light | 36 ± 32 | 1.55 ± 1.24 | 1.45 ± 1.19 | 1.83 ± 1.32 |
| SOFA score | 8.4 ± 3.0 | — | — | — |
| IL-1β | 28.3 ± 14.1 | 0.64 ± 0.60 | 0.59 ± 0.56 | 0.78 ± 0.70 |
| IL-6 | 296 ± 1054 | 5.43 ± 1.70 | 4.95 ± 1.42 | 6.72 ± 1.73 |
| IL-8 | 89 ± 105 | 6.60 ± 1.12 | 6.37 ± 1.00 | 7.21 ± 1.22 |
| TNF-α | 14 ± 6.5 | 1.87 ± 0.60 | 1.81 ± 0.53 | 2.02 ± 0.74 |
Mean ± SD unless otherwise specified.
Pg/ml, pictogram per mililitre; NPX, Normalized Protein eXpression, Log2 scale; ICU, Intensive Care Unit; SOFA, Sequential Organ Failure Assessment; IL, interleukin; TNF, tumour necrosis factor.
a
Excluding one outlier with 66 days between detubation and discharge to ward.